pmid	doi	year	title	Hugo_Symbol
33764527	10.1002/cncr.33454	2022	Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenström macroglobulinemia.	IL6
34009095	10.1080/09273948.2021.1878233	2022	Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.	IL6
34039950	10.1038/s41408-021-00493-5	2022	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	IL6
34078642	10.1158/1055-9965.EPI-20-1704	2022	Cytokine Levels at Birth in Children Who Developed Acute Lymphoblastic Leukemia.	IL6
34131000	10.1158/1078-0432.CCR-20-4167	2022	Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study.	IL6
34509934	10.1016/j.intimp.2021.108138	2022	LncRNA THUMPD3-AS1 enhances the proliferation and inflammatory response of chondrocytes in osteoarthritis.	IL6
34542753	10.1007/s10517-021-05268-3	2022	Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.	IL6
34691064	10.3389/fimmu.2021.750114	2022	Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults.	IL6
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	IL6
34935301	10.1002/vms3.694	2022	Neutrophilic leucocytosis induced by granulocyte colony-stimulating factor and interleukin-6 in canine primary lung adenocarcinoma.	IL6
35008292	10.3390/cancers14010128	2022	Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma.	IL6
35014680	10.3892/mmr.2022.12592	2022	Role of TGM2 in T‑cell lymphoblastic lymphoma via regulation of IL‑6/JAK/STAT3 signalling.	IL6
35021606	10.3324/haematol.2021.280003	2022	Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.	IL6
35147475	10.1080/10428194.2022.2038373	2022	Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.	IL6
35158867	10.3390/cancers14030598	2022	Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.	IL6
35186744	10.3389/fonc.2022.808511	2022	Clinical Features, Diagnosis, Management and Prognosis of Primary Intraocular Lymphoma.	IL6
35187467	10.1016/j.clinpr.2022.100137	2022	Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study.	IL6
35345499	10.2147/IMCRJ.S345149	2022	A Case of Intraocular Lymphoma Diagnosed by Subretinal Fluid Biopsy.	IL6
35349392	10.1080/15384101.2022.2054096	2022	MCL-1 is a clinically targetable vulnerability in breast cancer.	IL6
35399163	10.1155/2022/1840589	2022	Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease.	IL6
35432366	10.3389/fimmu.2022.856039	2022	IL-6 and IL-10 Are Associated With Gram-Negative and Gram-Positive Bacteria Infection in Lymphoma.	IL6
35546979	10.22092/ari.2021.356202.1803	2022	Renoprotective Potential of the Ultra-Pure Lipopolysaccharide from Rhodobacter Sphaeroides on Acutely Injured Kidneys in an Animal Model.	IL6
35642002	10.1186/s12967-022-03451-2	2022	Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.	IL6
35884913	10.3390/biomedicines10071608	2022	Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.	IL6
35997599	10.1089/vim.2021.0224	2022	Expression Pattern of Inflammatory and Anti-Inflammatory Cytokines and Key Differential Transcription Factors in Peripheral Blood Mononuclear Cells of Iranian Coronavirus Disease 2019 Patients with Different Disease Severity.	IL6
36098043	10.1002/jcla.24689	2022	Logistic regression models of cytokines in differentiating vitreoretinal lymphoma from uveitis.	IL6
30443842	10.1007/s12253-018-0536-z	2021	The Expression of Interferon Gamma (IFN-γ) and Interleukin 6 (IL6) in Patients with Acute Lymphoblastic Leukemia (ALL).	IL6
32118299	10.1111/bjh.16523	2021	Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.	IL6
32270320	10.1007/s00403-020-02062-5	2021	The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.	IL6
32614271	10.1089/jir.2020.0012	2021	Interleukin-6-Mediated Inflammation May Cause Methotrexate-Induced Leukoencephalopathy.	IL6
32669372	10.1158/1078-0432.CCR-20-1434	2021	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.	IL6
32767331	10.26355/eurrev_202008_22488	2021	Correlations of IL-6 and IL-10 gene polymorphisms with childhood acute lymphoblastic leukemia.	IL6
32808859	10.1080/10799893.2020.1808678	2021	Regulation of cell activation by A20 through STAT signaling in acute lymphoblastic leukemia.	IL6
32859946	10.1038/s41540-020-00145-7	2021	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.	IL6
32926412	10.1002/jmv.26516	2021	Evaluation of IL-2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ cytokines in HIV/HHV-8 coinfection.	IL6
32998963	10.1158/1078-0432.CCR-20-1739	2021	Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.	IL6
33154497	10.1038/s41598-020-76206-y	2021	Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis.	IL6
33246336	10.1093/humrep/deaa291	2021	N-acetylcysteine protects ovarian follicles from ischemia-reperfusion injury in xenotransplanted human ovarian tissue.	IL6
33247999	10.1111/cas.14752	2021	Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.	IL6
33397158	10.1080/14737140.2021.1853531	2021	High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL).	IL6
33403488	10.1007/s12015-020-10107-5	2021	Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient.	IL6
33578562	10.1097/MD.0000000000024598	2021	Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma.	IL6
33771682	10.1016/j.etap.2021.103639	2021	Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-κB/P65 pathway.	IL6
33907185	10.1038/s41421-021-00255-4	2021	CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy.	IL6
33958640	10.1038/s41598-021-88963-5	2021	Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT.	IL6
34071407	10.3390/cancers13112665	2021	Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.	IL6
34090412	10.1186/s12890-021-01553-z	2021	EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.	IL6
34535012	10.1182/bloodadvances.2021004562	2021	Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations.	IL6
28018176	10.3389/fncel.2016.00283	2020	Activated Microglia Induce Bone Marrow Mesenchymal Stem Cells to Produce Glial Cell-Derived Neurotrophic Factor and Protect Neurons Against Oxygen-Glucose Deprivation Injury.	IL6
28337303		2020	The involvement and possible mechanism of NR4A1 in chondrocyte apoptosis during osteoarthritis.	IL6
29593668	10.3389/fmicb.2018.00380	2020	Simulation Study of cDNA Dataset to Investigate Possible Association of Differentially Expressed Genes of Human THP1-Monocytic Cells in Cancer Progression Affected by Bacterial Shiga Toxins.	IL6
29911923	10.1080/10428194.2018.1461861	2020	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.	IL6
30333224	10.1158/1078-0432.CCR-18-1047	2020	Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.	IL6
30368882	10.1002/jcb.27671	2020	MAPKs and NF-κB-mediated acrylamide-induced neuropathy in rat striatum and human neuroblastoma cells SY5Y.	IL6
30668205	10.1080/10428194.2018.1554861	2020	Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment.	IL6
30825517	10.1016/j.exphem.2019.02.005	2020	Difference in megakaryocyte expression of GATA-1, IL-6, and IL-8 associated with maintenance of platelet counts in patients with plasma cell neoplasm with dysmegakaryopoiesis.	IL6
31355491	10.1111/imr.12768	2020	Cellular therapy: Immune-related complications.	IL6
31417180	10.1038/s41388-019-0921-4	2020	T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7.	IL6
31432169	10.3892/mmr.2019.10565	2020	Inhibition of microRNA‑124‑3p protects against acute myocardial infarction by suppressing the apoptosis of cardiomyocytes.	IL6
31515941	10.15252/emmm.201910576	2020	The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma.	IL6
31561022	10.1016/j.vetimm.2019.109940	2020	Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation.	IL6
31568628	10.1111/jcmm.14653	2020	Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.	IL6
31599429	10.26355/eurrev_201909_19020	2020	Influence of lncRNA-MALAT1 on neuronal apoptosis in rats with cerebral infarction through regulating the ERK/MAPK signaling pathway.	IL6
31601188	10.1186/s12885-019-6057-7	2020	Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.	IL6
31678006	10.1016/j.bmcl.2019.126743	2020	Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.	IL6
31886296	10.1155/2019/2137538	2020	Impact of SNPs/Haplotypes of <i>IL10</i> and <i>IFNG</i> on the Development of Diffuse Large B-Cell Lymphoma.	IL6
31894295	10.3892/ijmm.2019.4434	2020	MicroRNA‑15a‑5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP‑2 signaling pathway.	IL6
32034308	10.1038/s41388-020-1183-x	2020	Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma.	IL6
32124188	10.1007/s10552-020-01266-4	2020	Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study.	IL6
32312819	10.1073/pnas.1913707117	2020	Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells.	IL6
32362606	10.4103/jcrt.JCRT_137_17	2020	Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study.	IL6
32457601	10.3389/fphar.2020.00519	2020	An Integrative Pharmacology-Based Analysis of Refined Qingkailing Injection Against Cerebral Ischemic Stroke: A Novel Combination of Baicalin, Geniposide, Cholic Acid, and Hyodeoxycholic Acid.	IL6
32473488	10.1016/j.leukres.2020.106371	2020	High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era.	IL6
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	IL6
32673688	10.1016/j.exphem.2020.07.003	2020	Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome.	IL6
28674400	10.1038/s41598-017-04890-4	2019	Endotoxin tolerance in mast cells, its consequences for IgE-mediated signalling, and the effects of BCL3 deficiency.	IL6
29496539	10.1016/j.canlet.2018.02.036	2019	Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.	IL6
29504848	10.1080/08916934.2018.1446525	2019	Signalling pathways identified in salivary glands from primary Sjögren's syndrome patients reveal enhanced adipose tissue development.	IL6
29866021	10.2174/1871520618666180604093802	2019	Curcumin Modulates Glycolytic Metabolism and Inflammatory Cytokines via Nrf 2 in Dalton's Lymphoma Ascites Cells In Vivo.	IL6
29880584	10.1158/2159-8290.CD-17-1319	2019	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.	IL6
30066022	10.1007/s00210-018-1550-0	2019	Perindopril regulates the inflammatory mediators, NF-κB/TNF-α/IL-6, and apoptosis in cisplatin-induced renal dysfunction.	IL6
30097433	10.1158/1078-0432.CCR-18-0426	2019	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.	IL6
30217873	10.1158/0008-5472.CAN-18-0831	2019	Neonatal Inflammatory Markers Are Associated with Childhood B-cell Precursor Acute Lymphoblastic Leukemia.	IL6
30458319	10.1016/j.leukres.2018.11.004	2019	Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology.	IL6
30485406	10.1111/bjh.15689	2019	Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion.	IL6
30592279	10.3892/mmr.2018.9783	2019	Protective effect of dihydromyricetin revents fatty liver through nuclear factor‑κB/p53/B‑cell lymphoma 2‑associated X protein signaling pathways in a rat model.	IL6
30628689	10.3892/mmr.2019.9827	2019	Low‑dose lipopolysaccharide inhibits neuronal apoptosis induced by cerebral ischemia/reperfusion injury via the PI3K/Akt/FoxO1 signaling pathway in rats.	IL6
30864712	10.3892/mmr.2019.10014	2019	Estrogen receptor β suppresses inflammation and the progression of prostate cancer.	IL6
31108175	10.1016/j.fsi.2019.05.034	2019	Ctenopharyngodon Idella STAT3 alleviates autophagy by up-regulating BCL-2 expression.	IL6
31173173	10.3892/ijmm.2019.4230	2019	Hydroxysafflor Yellow A mitigated myocardial ischemia/reperfusion injury by inhibiting the activation of the JAK2/STAT1 pathway.	IL6
31180523	10.3892/mmr.2019.10273	2019	Resveratrol alleviates inflammatory injury and enhances the apoptosis of fibroblast‑like synoviocytes via mitochondrial dysfunction and ER stress in rats with adjuvant arthritis.	IL6
27098052	10.1039/c6lc00229c	2018	In vitro micro-physiological immune-competent model of the human skin.	IL6
27489357	10.18632/oncotarget.10966	2018	Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma.	IL6
27924864	10.1038/srep38671	2018	Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.	IL6
28061377	10.1016/j.bcmd.2016.12.011	2018	TNF-α increases in the CSF of children with acute lymphoblastic leukemia before CNS relapse.	IL6
28092896	10.1182/blood-2016-02-700575	2018	Primary effusion lymphoma and concurrent progressive Kaposi sarcoma associated with elevated interleukin-6.	IL6
28341757	10.1158/1055-9965.EPI-16-1012	2018	Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.	IL6
28656237	10.3892/mmr.2017.6865	2018	Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‑6/JAK1/STAT3 signaling pathway.	IL6
28713932	10.3892/mmr.2017.6927	2018	Human trypsin inhibitor reduces the apoptosis of lipopolysaccharide‑induced human kidney‑2 cells by promoting mitochondrial fusion.	IL6
28791394	10.3892/mmr.2017.7158	2018	Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.	IL6
28847988	10.1158/1535-7163.MCT-17-0041	2018	Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.	IL6
29039526	10.3892/mmr.2017.7771	2018	Promoting effects of IL‑23 on myocardial ischemia and reperfusion are associated with increased expression of IL‑17A and upregulation of the JAK2‑STAT3 signaling pathway.	IL6
29039549	10.3892/mmr.2017.7782	2018	Downregulation of caspase‑3 alleviates Mycoplasma pneumoniae‑induced apoptosis in alveolar epithelial cells.	IL6
29039568	10.3892/mmr.2017.7788	2018	3,3'‑Diindolylmethane attenuates cardiomyocyte hypoxia by modulating autophagy in H9c2 cells.	IL6
29045804	10.17305/bjbms.2017.2457	2018	Matrine induced G0/G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia (T-ALL) cells.	IL6
29074500	10.1182/blood-2017-08-802413	2018	Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.	IL6
29114012	10.1530/JOE-17-0359	2018	Cbl downregulation increases RBP4 expression in adipocytes of female mice.	IL6
29115547	10.3892/mmr.2017.7981	2018	Preventive effect of hesperidin modulates inflammatory responses and antioxidant status following acute myocardial infarction through the expression of PPAR‑γ and Bcl‑2 in model mice.	IL6
29207118	10.3892/mmr.2017.8170	2018	Oxysophoridine rescues spinal cord injury via anti‑inflammatory, anti‑oxidative stress and anti‑apoptosis effects.	IL6
29257294	10.3892/mmr.2017.8266	2018	Baicalein protects against endothelial cell injury by inhibiting the TLR4/NF‑κB signaling pathway.	IL6
29336471	10.3892/ijmm.2018.3392	2018	Neuroprotective effects of p53/microRNA‑22 regulate inflammation and apoptosis in subarachnoid hemorrhage.	IL6
29393473	10.3892/mmr.2018.8543	2018	Protective effects of N(2)‑L‑alanyl‑L‑glutamine mediated by the JAK2/STAT3 signaling pathway on myocardial ischemia reperfusion.	IL6
29510136	10.1016/j.bbrc.2018.03.010	2018	Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells.	IL6
30068867	10.1248/bpb.b17-00930	2018	Qiliqiangxin Protects against Renal Injury in Rat with Cardiorenal Syndrome Type I through Regulating the Inflammatory and Oxidative Stress Signaling.	IL6
25382321		2017	Immune regulation of hydrogen sulfide in children with acute lymphoblastic leukemia.	IL6
25760916	10.3109/09273948.2014.1002568	2017	Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma.	IL6
27025651	10.1093/nar/gkw205	2017	MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1.	IL6
27039262	10.1016/j.jid.2016.03.024	2017	Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.	IL6
27049586	10.1016/j.jim.2016.03.005	2017	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.	IL6
27076371	10.1158/2159-8290.CD-16-0040	2017	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.	IL6
27156226	10.1016/j.ejca.2016.03.080	2017	The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.	IL6
27394196	10.1002/cam4.714	2017	Prediction of survival of diffuse large B-cell lymphoma patients via the expression of three inflammatory genes.	IL6
27430206	10.1016/j.fertnstert.2016.06.035	2017	High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.	IL6
27430346	10.3892/mmr.2016.5513	2017	Protective effect of cannabidiol on hydrogen peroxide‑induced apoptosis, inflammation and oxidative stress in nucleus pulposus cells.	IL6
27488529	10.1158/0008-5472.CAN-16-0595	2017	TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.	IL6
27573177	10.3892/mmr.2016.5665	2017	Protective effect of active perfusion in porcine models of acute myocardial ischemia.	IL6
27598116	10.3390/molecules21091169	2017	Atractylodin Inhibits Interleukin-6 by Blocking NPM-ALK Activation and MAPKs in HMC-1.	IL6
27599675	10.3892/mmr.2016.5721	2017	Co‑culture of ﬁbroblast‑like synoviocytes with umbilical cord‑mesenchymal stem cells inhibits expression of pro‑inﬂammatory proteins, induces apoptosis and promotes chondrogenesis.	IL6
27600942	10.3892/mmr.2016.5695	2017	Effects of endomorphin-1 postconditioning on myocardial ischemia/reperfusion injury and myocardial cell apoptosis in a rat model.	IL6
27667327	10.1002/pbc.26253	2017	Chemotherapeutic treatment reduces circulating levels of surfactant protein-D in children with acute lymphoblastic leukemia.	IL6
27813533	10.1038/bcj.2016.95	2017	Transgenic mouse model of IgM<sup>+</sup> lymphoproliferative disease mimicking Waldenström macroglobulinemia.	IL6
27840933	10.3892/mmr.2016.5919	2017	Nobiletin ameliorates isoflurane-induced cognitive impairment via antioxidant, anti-inflammatory and anti-apoptotic effects in aging rats.	IL6
27913530	10.1182/asheducation-2016.1.567	2017	Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.	IL6
27930538	10.1097/MD.0000000000005503	2017	Binocular indirect ophthalmo microscope-assistant gas-perfused pars plana vitrectomy: A novel technique for vitreous sample acquisition.	IL6
28031410	10.1158/1541-7786.MCR-16-0344	2017	Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma.	IL6
28056186	10.1080/15548627.2016.1271516	2017	Tampering with cancer chemoresistance by targeting the TGM2-IL6-autophagy regulatory network.	IL6
28157416	10.1089/jop.2016.0132	2017	Gradient Boosted Decision Tree Classification of Endophthalmitis Versus Uveitis and Lymphoma from Aqueous and Vitreous IL-6 and IL-10 Levels.	IL6
28190086	10.1007/s00441-017-2576-1	2017	MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.	IL6
28199343	10.1371/journal.pone.0171623	2017	Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study.	IL6
28246881	10.1007/s00262-017-1961-7	2017	Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10.	IL6
25564959	10.3109/08820139.2014.989328	2016	CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B-cell lymphoma (DLBCL).	IL6
25601959	10.1158/1078-0432.CCR-14-1678	2016	FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.	IL6
25833228	10.1111/aos.12733	2016	Correlation between measurement of IL-10 and IL-6 in paired aqueous humour and vitreous fluid in primary vitreoretinal lymphoma.	IL6
25915535	10.18632/oncotarget.3837	2016	Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.	IL6
25951043	10.1080/15548627.2015.1017192	2016	The role of STAT3 in autophagy.	IL6
25962811	10.1158/1055-9965.EPI-14-1355	2016	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.	IL6
26043790	10.1080/15548627.2015.1052205	2016	Cocaine-mediated microglial activation involves the ER stress-autophagy axis.	IL6
26073757	10.1038/leu.2015.140	2016	Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.	IL6
26080800	10.1007/s11060-015-1843-9	2016	STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.	IL6
26087799		2016	Treatment of multicentric Castleman&amp;rsquo;s disease in HIV-1 infected and uninfected patients: a systematic review.	IL6
26367092	10.1097/ICU.0000000000000213	2016	Primary CNS lymphoma.	IL6
26381542	10.1016/j.bbamcr.2015.09.018	2016	Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression.	IL6
26384320	10.1158/1078-0432.CCR-14-0466	2016	Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).	IL6
26444983	10.1186/s13045-015-0205-6	2016	Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.	IL6
26546525		2016	Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.	IL6
26658701	10.1093/cid/civ996	2016	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).	IL6
26784544	10.1172/JCI81041	2016	Tetraspanin CD37 protects against the development of B cell lymphoma.	IL6
26796245	10.3892/mmr.2016.4805	2016	Protective effect of paeoniflorin on inflammation and apoptosis in the cerebral cortex of a transgenic mouse model of Alzheimer's disease.	IL6
27463474	10.3109/10428199109103373	2016	In vitro Activation of B-CLL Cells.	IL6
24097071	10.1007/s00535-013-0885-z	2015	Functions and regulation of MUC13 mucin in colon cancer cells.	IL6
24493366	10.1002/hon.2121	2015	Elevated serum levels of interleukin-6 in endemic Burkitt lymphoma in Ghana.	IL6
24560125	10.1016/j.survophthal.2013.12.001	2015	Primary intraocular lymphoma.	IL6
24705981	10.1634/theoncologist.2013-0407	2015	STAT3 inhibitors: finding a home in lymphoma and leukemia.	IL6
25037968	10.1007/s10103-014-1624-2	2015	Effect of low-level laser therapy on inflammatory mediator release during chemotherapy-induced oral mucositis: a randomized preliminary study.	IL6
25131731	10.1016/j.vaccine.2014.07.103	2015	Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant.	IL6
25216518	10.18632/oncotarget.2253	2015	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.	IL6
25240629	10.1016/j.ophtha.2014.07.048	2015	Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease.	IL6
25258254	10.1007/s11060-014-1622-z	2015	Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.	IL6
25269574	10.3892/mmr.2014.2591	2015	Role and mechanisms of microRNA‑503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells.	IL6
25294016	10.1002/ajh.23868	2015	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.	IL6
25304617	10.1007/s00432-014-1842-9	2015	Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma.	IL6
25448491	10.1016/j.exphem.2014.10.009	2015	Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.	IL6
25455270	10.1016/j.beha.2014.10.014	2015	Advances in T-cell therapy for ALL.	IL6
25480498	10.3324/haematol.2014.116087	2015	Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator.	IL6
25647547	10.3892/mmr.2015.3289	2015	Icariin protects H9c2 cardiomyocytes from lipopolysaccharide‑induced injury via inhibition of the reactive oxygen species‑dependent c‑Jun N‑terminal kinases/nuclear factor-κB pathway.	IL6
25704763	10.1002/ijc.29494	2015	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.	IL6
25805671	10.4274/tjh.2013.0325	2015	Are the high serum interleukin-6 and vascular endothelial growth factor levels useful prognostic markers in aggressive non-hodgkin lymphoma patients?	IL6
25838973	10.1186/s40164-015-0005-2	2015	CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.	IL6
26124333		2015	Protective Effect of Leuprorelin on Radiation-induced Intestinal Toxicity.	IL6
26245900	10.1074/jbc.M115.657833	2015	The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.	IL6
23557330	10.1111/cas.12167	2014	Clinical significance of CD163⁺ tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma.	IL6
23647063	10.3109/10428194.2013.802314	2014	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin.	IL6
23874201	10.1371/journal.ppat.1003484	2014	Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies.	IL6
24008079	10.1016/j.cyto.2013.08.002	2014	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.	IL6
24059848	10.3109/1354750X.2013.840799	2014	Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies.	IL6
24141626	10.1158/1078-0432.CCR-13-1879	2014	Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.	IL6
24488825	10.1002/ijc.28724	2014	Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.	IL6
24613204	10.1016/j.intimp.2014.02.024	2014	Curcumin attenuates carcinogenesis by down regulating proinflammatory cytokine interleukin-1 (IL-1α and IL-1β) via modulation of AP-1 and NF-IL6 in lymphoma bearing mice.	IL6
24625985	10.1038/cddis.2014.93	2014	URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.	IL6
24832086	10.1093/carcin/bgu106	2014	Maternal metabolic perturbations elicited by high-fat diet promote Wnt-1-induced mammary tumor risk in adult female offspring via long-term effects on mammary and systemic phenotypes.	IL6
24887301	10.5414/CN108132	2014	Proteinuria is a simple sign of systemic inflammation that leads to a poor prognosis in individuals affected with non-Hodgkin lymphoma.	IL6
25071000	10.4269/ajtmh.13-0616	2014	Interleukin-6 and interleukin-10 gene promoter polymorphisms and risk of endemic Burkitt lymphoma.	IL6
22414145	10.1111/j.1440-1789.2012.01310.x	2013	TLR4, IL-6, IL-18, MyD88 and HMGB1 are highly expressed in intracranial inflammatory lesions and the IgG4/IgG ratio correlates with TLR4 and IL-6.	IL6
22475215	10.3109/10428194.2012.666662	2013	Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia.	IL6
22491065	10.1038/icb.2012.17	2013	IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells.	IL6
22552607	10.1007/s00277-012-1479-1	2013	Primary intraocular lymphoma in a patient with systemic lupus erythematosus.	IL6
22968454	10.1182/blood-2012-04-424630	2013	Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.	IL6
23169640	10.1073/pnas.1213764109	2013	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.	IL6
23190644	10.1038/gene.2012.55	2013	Common and specific signatures of gene expression and protein-protein interactions in autoimmune diseases.	IL6
23215766	10.3109/08830185.2012.737073	2013	HIV-1 Nef in macrophage-mediated disease pathogenesis.	IL6
23522566	10.1016/j.jcv.2013.02.022	2013	Increased IL-6 detection in adult and pediatric lymphoid tissue harboring parvovirus B19.	IL6
23706741	10.1016/j.cell.2013.04.034	2013	Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation.	IL6
23714608	10.1016/j.ophtha.2012.09.053	2013	Diagnostic criteria for primary ocular lymphoma.	IL6
21653647	10.1158/1055-9965.EPI-11-0162	2012	Profound deficit of IL10 at birth in children who develop childhood acute lymphoblastic leukemia.	IL6
21902578	10.3109/10428194.2011.621566	2012	Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.	IL6
21912394	10.1038/leu.2011.251	2012	IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes.	IL6
21919984	10.1111/j.1365-263X.2011.01175.x	2012	Proinflammatory cytokines during the initial phase of oral mucositis in patients with acute lymphoblastic leukaemia.	IL6
22071475	10.1038/jid.2011.351	2012	High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.	IL6
22113576	10.1007/s11764-010-0164-4	2012	Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.	IL6
22177381	10.1186/1476-511X-10-236	2012	Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression.	IL6
22190165	10.1002/ajh.22263	2012	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.	IL6
22490805	10.1182/blood-2011-09-377705	2012	HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice.	IL6
22661396	10.1007/s10384-012-0150-7	2012	Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma.	IL6
22723554	10.1182/blood-2012-01-401760	2012	Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma.	IL6
22912446	10.3382/ps.2012-02226	2012	Gene expression analysis of host spleen responses to Marek's disease virus infection at late tumor transformation phase.	IL6
19958292	10.1111/j.1755-3768.2009.01797.x	2011	Diagnosis of systemic metastatic retinal lymphoma.	IL6
20663948	10.3324/haematol.2009.019745	2011	Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.	IL6
20716621	10.1158/1055-9965.EPI-10-0389	2011	Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia.	IL6
20884685	10.1093/carcin/bgq200	2011	Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis.	IL6
21061265	10.1002/mc.20688	2011	Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes.	IL6
21198209	10.1117/1.3523368	2011	Development of combination tapered fiber-optic biosensor dip probe for quantitative estimation of interleukin-6 in serum samples.	IL6
21466366	10.5858/2010-0060-OA.1	2011	Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma.	IL6
21527584	10.1158/1055-9965.EPI-11-0037	2011	B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.	IL6
21617699	10.1038/leu.2011.113	2011	TLR4 knockout protects mice from radiation-induced thymic lymphoma by downregulation of IL6 and miR-21.	IL6
21875833	10.1188/11.ONF.E365-E372	2011	Disturbed sleep in pediatric patients with leukemia: the potential role of interleukin-6 (-174GC) and tumor necrosis factor (-308GA) polymorphism.	IL6
19558504	10.1111/j.1600-0609.2009.01307.x	2010	Primary cutaneous diffuse large B-cell lymphoma, leg type, with features simulating POEMS syndrome.	IL6
19773279	10.1136/oem.2008.044024	2010	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	IL6
19914024	10.1016/j.domaniend.2009.10.001	2010	Adipose tissue depots of Holstein cows are immune responsive: inflammatory gene expression in vitro.	IL6
20167370	10.1016/j.leukres.2010.01.027	2010	Multiple-cytokine-producing CD30-positive diffuse large B-cell lymphoma.	IL6
20167371	10.1016/j.leukres.2010.01.022	2010	Multiple-cytokine-producing, mixed-cellularity, classical Hodgkin lymphoma with B symptoms and minimal-change nephrotic syndrome.	IL6
20306666		2010	Pro-inflammatory cytokines and depression in patients with acute leukemia.	IL6
20400291	10.1016/j.ejca.2010.03.026	2010	Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL.	IL6
20507572	10.1186/1471-2172-11-26	2010	Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells.	IL6
18528464		2009	Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.	IL6
18800145	10.1038/leu.2008.255	2009	Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.	IL6
19430534	10.1371/journal.pone.0005500	2009	Functional analysis of a dominant negative mutation of interferon regulatory factor 5.	IL6
19469019	10.1111/j.1349-7006.2009.01083.x	2009	Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.	IL6
19484437	10.1007/s10384-009-0662-y	2009	Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid.	IL6
19508433	10.1111/j.1600-0609.2009.01288.x	2009	Genetic variants in immunoregulatory genes and risk for childhood lymphomas.	IL6
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	IL6
19585355	10.1080/09273940802702553	2009	Cytokine and molecular analyses of intraocular lymphoma.	IL6
19617629	10.1074/jbc.M109.019786	2009	Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10.	IL6
19626047	10.1038/leu.2009.139	2009	IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.	IL6
19717648	10.1182/blood-2009-01-201111	2009	C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.	IL6
19738032	10.1182/blood-2009-03-209601	2009	A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.	IL6
17823310	10.1182/blood-2007-04-087775	2008	HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration.	IL6
18160665	10.1182/blood-2007-09-111948	2008	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.	IL6
18190463	10.1111/j.1365-2257.2006.00890.x	2008	Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment.	IL6
18297540	10.1080/10428190701861678	2008	Granulocyte colony-stimulating factor and interleukin-6 production by myelodysplastic syndrome blasts.	IL6
18398743	10.1080/10428190801888696	2008	Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators.	IL6
18479302	10.1111/j.1751-553X.2007.00951.x	2008	Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma.	IL6
18633131	10.1182/blood-2007-09-111658	2008	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.	IL6
18661266	10.1007/s10384-008-0519-9	2008	Treatment of primary intraocular lymphoma with intravitreal methotrexate.	IL6
16690518	10.1080/10428190500361029	2007	Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.	IL6
17309100	10.1002/pmic.200600366	2007	Screening the human serum proteome for genotype-phenotype associations: an analysis of the IL6 -174G&gt;C polymorphism.	IL6
17373716	10.1002/pros.20553	2007	Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.	IL6
17496310	10.1093/annonc/mdm132	2007	Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma.	IL6
17591892	10.1167/iovs.07-0008	2007	Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma.	IL6
16389181	10.1016/S1470-2045(05)70434-4	2006	Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium.	IL6
16449530	10.1182/blood-2005-10-4160	2006	Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma.	IL6
16573548	10.1111/j.1432-2277.2006.00278.x	2006	The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)-treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization.	IL6
16732314	10.1038/sj.onc.1209711	2006	BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription.	IL6
15223651	10.1080/10428190410001712225	2005	Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.	IL6
15610530	10.1111/j.0022-202X.2004.23497.x	2005	Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways.	IL6
15686457	10.1111/j.1365-2141.2004.05353.x	2005	Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma.	IL6
15772702	10.1038/sj.leu.2403716	2005	HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3.	IL6
16009564	10.1016/j.cyto.2005.05.007	2005	Role of IL-6 and CD23 in the resistance to growth arrest and apoptosis in LCL41 B lymphoma cells.	IL6
12969979	10.1182/blood-2003-04-1048	2004	Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.	IL6
15070705	10.1182/blood-2003-08-2860	2004	IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma.	IL6
15152368	10.1002/hon.725	2004	Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy.	IL6
15315756	10.1016/j.cell.2004.08.006	2004	AID is required for c-myc/IgH chromosome translocations in vivo.	IL6
15507390	10.1016/j.clim.2004.08.010	2004	Heterozygote AG variant of -596 A/G IL-6 gene polymorphism is a marker for cutaneous T-cell lymphoma (CTCL).	IL6
12153001	10.1080/10428190290026385	2003	Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL).	IL6
12494410	10.1002/jca.10039	2003	Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo.	IL6
12769790	10.2174/1568005033481150	2003	Viral latent proteins as targets for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) induced lymphoma.	IL6
12038454	10.1034/j.1600-0609.2002.01609.x	2002	Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.	IL6
12226829	10.1002/jmv.10218	2002	Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line.	IL6
11205285		2001	Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells.	IL6
11238858	10.1128/JVI.75.7.3325-3334.2001	2001	Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.	IL6
10641032	10.1002/(sici)1099-1069(199909)17:3&lt;117::aid-hon640&gt;3.0.co;2-1	2000	Preferential type 1-1 cytokine gene expressions in peripheral T-cell lymphomas.	IL6
10752984	10.3109/10428190009089433	2000	Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis.	IL6
10965529		2000	[Kaposi's disease and HHV8: a new model of virus-induced tumorigenesis].	IL6
10995008	10.1038/sj.leu.2401869	2000	A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes.	IL6
10081633	10.1034/j.1399-0012.1999.t01-2-130106.x	1999	Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders.	IL6
10214873	10.1038/sj.leu.2401371	1999	Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines.	IL6
10479534	10.1006/clim.1999.4760	1999	The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6.	IL6
9922045	10.3109/10428199809057614	1999	Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.	IL6
9477120	10.3109/10428199709058305	1998	Regulation of hematopoiesis by microvascular endothelium.	IL6
9698872	10.1590/s0074-02761998000300019	1998	Immune dysfunction and the pathogenesis of AIDS-associated non-Hodgkin's lymphoma.	IL6
8833392	10.3109/10428199609052418	1997	Potential use of recombinant human interleukin-6 in clinical oncology.	IL6
8833403	10.3109/10428199609052429	1997	C-kit ligand (SCF) in human multiple myeloma cells.	IL6
8907629		1997	In vitro expansion of CD34+ cells from peripheral blood of myeloma and lymphoma patients.	IL6
8907632		1997	Peripheral blood CD34+ cells: method of purification and ex vivo expansion.	IL6
8951770	10.3109/10428199609074358	1997	Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.	IL6
9031116	10.3109/10428199609054838	1997	Effects of interferon-alpha and -gamma on B cell differentiation in macroglobulinemia.	IL6
9078302	10.1016/s0165-4608(96)00191-4	1997	Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders.	IL6
9081710	10.1038/sj.gt.3300363	1997	Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells.	IL6
9130625	10.3109/10428199709042507	1997	Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans-retinoic-acid.	IL6
9169458	10.1074/jbc.272.23.14883	1997	HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors.	IL6
9172801	10.3109/10428199609093434	1997	Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia.	IL6
9324301	10.1038/sj.leu.2400757	1997	Expression of interleukin-6 receptors by pediatric acute lymphoblastic leukemia cells with the t(4;11) translocation: a possible target for therapy with recombinant IL6-Pseudomonas exotoxin.	IL6
9350884	10.1111/j.1651-2227.1997.tb14807.x	1997	Interleukin 6, but not tumour necrosis factor-alpha, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy.	IL6
8552662	10.1073/pnas.93.1.465	1996	Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6.	IL6
8580819	10.3109/10428199509064937	1996	Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation.	IL6
8844998	10.1006/jmbi.1996.0516	1996	Regulation of HIV-1 gene expression by NF-IL6.	IL6
8913315	10.1016/0145-2126(96)00029-x	1996	Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection.	IL6
7622142	10.1002/hon.2900130302	1995	IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV.	IL6
7800944	10.1016/s0923-2516(07)80021-5	1995	In vitro analysis of HIV- and non-HIV-infected monocytes/macrophages from healthy subjects and patients with malignant tumours.	IL6
7817670	10.2340/0001555574355357	1995	Presence of Epstein-Barr virus in cutaneous lesions of mycosis fungoides and Sézary syndrome.	IL6
7994626		1995	[Interleukins and HIV disease].	IL6
7516922		1994	In vitro expansion of CD34+ cells mobilized with chemotherapy and G-CSF.	IL6
7920182		1994	Selective expression of the murine homologue of the G-protein-coupled receptor BLR1 in B cell differentiation, B cell neoplasia and defined areas of the cerebellum.	IL6
7950920	10.3109/10428199409049683	1994	Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with IL2 and soluble CD23.	IL6
7950924	10.3109/10428199409049687	1994	Determination of IL6, IL1, and IL4 in the plasma of patients with multiple myeloma.	IL6
8113688	10.1084/jem.179.3.961	1994	The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.	IL6
1296932	10.1002/hon.2900100605	1993	Production of multiple cytokines by Hodgkin's disease derived cell lines.	IL6
1450074	10.1093/annonc/3.suppl_4.s13	1993	Activation of cytokines in Hodgkin's disease.	IL6
1490358	10.1007/978-3-642-77633-5_27	1993	Genes expressed selectively in plasmacytomas: markers of differentiation and transformation.	IL6
1381718	10.1172/JCI115920	1992	Interleukin-7 is a growth factor for Sézary lymphoma cells.	IL6
1772970		1992	Polymerase chain reaction polymorphisms in HLA-DQ alpha and IL6 from Mongoloid and Caucasoid populations.	IL6
1818294		1992	IL6 and lymphoproliferative disorders.	IL6
2495224	10.1002/eji.1830190222	1989	Characterization and growth factor requirements of SJL lymphomas. II. Interleukin 5 dependence of the in vitro cell line, cRCS-X, and influence of other cytokines.	IL6
2783586	10.1016/0165-5728(89)90177-x	1989	T cell lines established from multiple sclerosis cerebrospinal fluid T cells using human retroviruses.	IL6
